Vitiligo Treatment in Clovis & Fresno, CA
Vitiligo is a chronic autoimmune skin condition that causes the loss of skin pigmentation in patches, resulting in distinctive white or light areas against the surrounding natural skin tone. While vitiligo is not physically harmful, its visible nature can have a profound impact on self-confidence and emotional wellbeing — particularly in individuals with darker skin tones where the contrast is more pronounced. At Dehesa Dermatology, board-certified dermatologist Dr. Luis A. Dehesa offers compassionate, evidence-based vitiligo care including the latest repigmentation therapies for patients throughout Clovis, Fresno, and the Central Valley.
What Is Vitiligo?
Vitiligo occurs when melanocytes — the pigment-producing cells responsible for skin, hair, and eye color — are destroyed by the immune system. The result is the gradual loss of pigment in affected areas, producing sharply demarcated white patches on the skin. Vitiligo affects approximately 1% of the global population and can develop at any age, though it most commonly begins before age 30. It occurs in all skin types and ethnicities, but is often more visible and more psychologically impactful in patients with medium to dark skin tones.
The course of vitiligo is unpredictable — some patients experience slow, limited spread over many years, while others progress rapidly. Stress, sunburn, skin trauma (the Koebner phenomenon), and certain illnesses can trigger new patches. Vitiligo is associated with other autoimmune conditions, including thyroid disease, type 1 diabetes, alopecia areata, and Addison’s disease — making a systemic evaluation an important part of comprehensive vitiligo care. For patients with co-existing autoimmune conditions, our integrated approach through our rheumatology team and complex medical dermatology services provides an added layer of specialist oversight.
Types of Vitiligo
- Non-Segmental (Generalized) Vitiligo: The most common type, in which patches appear symmetrically on both sides of the body and may spread progressively over time. Often begins on the face, hands, or areas around body openings.
- Segmental Vitiligo: Affects only one side or segment of the body, typically following a dermatomal distribution. Usually spreads quickly for a period then stabilizes. Less likely to be associated with other autoimmune conditions than non-segmental vitiligo.
- Focal Vitiligo: One or a few small patches in an isolated area that do not spread widely. Sometimes an early presentation that later evolves into a more generalized pattern.
- Universal Vitiligo: The most extensive form, with depigmentation affecting more than 80% of the body surface. Rare.
Vitiligo Treatment Options at Dehesa Dermatology
While there is no cure for vitiligo, significant repigmentation is achievable with current treatments — particularly when therapy is started early before melanocyte populations in affected areas are fully depleted. At Dehesa Dermatology, we offer:
- Topical Corticosteroids: First-line treatment for localized vitiligo, particularly in areas away from the face and skin folds. Can halt progression and promote repigmentation in some patients.
- Topical Calcineurin Inhibitors: Tacrolimus and pimecrolimus — non-steroidal alternatives particularly suited for the face, eyelids, and other sensitive areas where prolonged steroid use is not appropriate.
- Topical JAK Inhibitors: Ruxolitinib cream (Opzelura) is the first FDA-approved topical treatment specifically for non-segmental vitiligo. Clinical trials have demonstrated meaningful repigmentation, particularly on the face, with a favorable safety profile.
- Narrowband UVB Phototherapy: One of the most effective treatments for widespread vitiligo. Controlled UV light exposure stimulates melanocyte migration from the hair follicle reservoir into depigmented skin. Requires multiple sessions per week for months — most effective for trunk and proximal extremity lesions.
- Oral JAK Inhibitors: Emerging systemic therapies that have shown promising results for rapidly progressing or extensive vitiligo in appropriate candidates.
- Sun Protection: Protecting depigmented skin from UV damage is critical — vitiligo patches completely lack the melanin that normally provides UV protection, making them highly susceptible to sunburn.
Frequently Asked Questions About Vitiligo
Is vitiligo contagious?
No — vitiligo is absolutely not contagious. It cannot be transmitted through touch, shared items, or any form of contact. Vitiligo is an autoimmune condition in which the body’s own immune system destroys pigment cells. Educating family members and the broader community about this fact is an important part of supporting patients living with vitiligo.
Can vitiligo be treated successfully?
Yes — significant repigmentation is achievable for many patients with current treatments, particularly topical JAK inhibitors and narrowband UVB phototherapy. Results are generally best when treatment begins early, before melanocyte populations in affected areas are fully depleted, and when vitiligo is in an active, spreading phase. Some areas of the body — particularly the face and trunk — respond better to repigmentation therapy than hands, feet, and other acral areas.
Does vitiligo spread over time?
Vitiligo is unpredictable — some patients experience limited, stable disease while others see progressive spreading over years. Factors that may trigger new patches or progression include physical trauma to the skin, sunburn, significant emotional stress, and certain illnesses. Active, spreading vitiligo is generally more responsive to treatment than stable, longstanding patches.
What is ruxolitinib cream and is it available at Dehesa Dermatology?
Ruxolitinib cream (Opzelura) is the first FDA-approved topical treatment specifically for non-segmental vitiligo in patients 12 years and older. It is a JAK inhibitor that reduces the autoimmune attack on melanocytes and allows repigmentation. Clinical studies showed meaningful face repigmentation in approximately 30% of patients after 24 weeks. Yes, ruxolitinib cream is available at Dehesa Dermatology for appropriate candidates — call (559) 951-9000 to schedule a consultation.
Is vitiligo associated with other health conditions?
Yes. Vitiligo is associated with other autoimmune conditions including thyroid disease (Hashimoto’s thyroiditis, Graves’ disease), type 1 diabetes, alopecia areata, and Addison’s disease. At Dehesa Dermatology, we screen for associated autoimmune conditions as part of vitiligo evaluation and coordinate care with relevant specialists when needed. Our on-site rheumatology team is available for patients whose vitiligo is part of a broader autoimmune picture.
How long does vitiligo treatment take to show results?
Vitiligo treatment is slow — repigmentation typically begins as small follicular dots of pigment within 3 to 6 months of consistent treatment and gradually expands. Full treatment responses take 12 to 24 months or longer. Patience and consistency are essential. Narrowband UVB phototherapy generally requires 3 sessions per week for 6 to 12 months for maximum benefit.
Does Dehesa Dermatology treat vitiligo patients from Fresno?
Yes. We treat vitiligo for patients from Fresno, Clovis, and throughout the Central Valley. Our practice is at 978 N Temperance Ave in Clovis, accessible from Fresno via Highway 168. Call (559) 951-9000 to schedule your vitiligo evaluation and learn about current treatment options including ruxolitinib cream and phototherapy.